This is a minor, immaterial item (small-scale product diversion, not a broad recall), so I'll mention it briefly as a footnote risk. Now I have enough to write a comprehensive preview.I now have a comprehensive picture. Let me write the earnings preview.# DexCom (DXCM) — Q2 2026 Earnings Preview Report Date: July 30, 2026 (after market close) | Current Price: ~$75 | 52-Week Range: $54.11 – $89.98
DexCom heads into its second-quarter print riding a wave of positive momentum: strong Q1 results, a well-received Investor Day, a positive CONNECT trial readout at ADA, and a string of sell-side price-target increases. The stock has run from the high-$50s/low-$60s in late April/early May to the mid-$70s today, touching a 52-week high near $78 in mid-June before pulling back modestly. Expectations are elevated heading into Wednesday's print.
Consensus for Q2 2026 calls for revenue of roughly $1.3 billion (+12% y/y) and adjusted EPS around $0.61 (+27% y/y), according to Zacks estimates. DexCom has beaten Street EPS estimates in each of the last four quarters, most recently posting non-GAAP EPS of $0.56 in Q1 2026 (vs. guidance-implied expectations), so the bar for a "beat" is meaningfully embedded in the stock.
DexCom's first quarter set an encouraging tone: - Worldwide revenue of $1.192 billion, up 15% reported / 12% organic, with U.S. revenue up 11% to $832 million and international revenue up 26% reported (17% organic) to $360 million. - Non-GAAP gross margin expanded to 63.5% (from 57.5% a year ago), non-GAAP operating margin hit 22.2%, and Adjusted EBITDA margin reached 30.6%. - Non-GAAP EPS of $0.56, up 75% y/y at the net income line; the company ended the quarter with ~$2.4 billion in cash. - Management reaffirmed full-year revenue guidance of $5.16–$5.25 billion (11–13% growth) and gross margin guidance of 63–64%, while raising non-GAAP operating margin guidance to 23–23.5% and Adjusted EBITDA margin guidance to 31–31.5%.
A key nuance from the Q1 call: management is holding gross margin guidance flat despite Q1 outperformance because of an embedded 50–100 bps headwind from fuel and resin costs tied to the geopolitical/oil environment — worth watching for an update.
1. G7 15 Day rollout is the biggest near-term operational story. DexCom expanded the G7 15 Day launch across all U.S. channels in Q1, and management guided to nearly 50% of the active base converting to the product by year-end, citing improved sensor accuracy and stronger NPS scores as drivers of both new-patient growth and retention. Investors will want an update on conversion pace and whether it's translating into sustained U.S. new-patient momentum (globally DexCom posted a record new-patient quarter in Q1, though the U.S. came in "close to" but not above a record for a fourth straight quarter — a point analysts pressed on).
2. Type 2 non-insulin (T2NIT) reimbursement keeps expanding. DexCom disclosed a new Prime Therapeutics win (effective this summer) that will push commercial coverage for the non-insulin T2 population above 7 million lives by year-end, building on the >6 million lives already covered across the three largest PBMs.
3. CONNECT randomized controlled trial data landed at ADA 2026 (June 6) — and looked strong. The trial DexCom teased on the Q1 call as potentially the "defining study" for the non-insulin population showed Dexcom G7 users achieved a 1.6% A1C reduction from baseline over 26 weeks — 0.9 percentage points better than routine care — with 68% of users reaching an A1C below 7.5% and 46% below 7.0%. This is the clinical evidence base management has pointed to as central to unlocking broader payer (especially CMS/Medicare) coverage.
4. Incremental CMS movement, but no final decision yet. In mid-June, CMS took a procedural step by adding CGM devices approved for dosing to its definition of durable medical equipment — characterized by advocacy groups as a step toward Medicare eligibility for the T2NIT population, but this is not the same as a coverage determination. Management has consistently framed a full National Coverage Determination as "a matter of time" rather than assumed in near-term guidance, so any incremental commentary on timing will be a key focus for the call and stock reaction.
5. Investor Day reset the long-term algorithm (May 14, 2026). DexCom introduced new long-range targets: 10%+ organic revenue growth every year through 2030, 2030 non-GAAP gross margin of 67–69%, operating margin of 29–30%, and Adjusted EBITDA margin of 36–37%. The board also authorized a new $1 billion share buyback program (through June 2027), replacing the prior program's remaining $250 million — a signal of confidence and capital-return intent alongside continued reinvestment (Ireland manufacturing ramp, R&D).
6. Product pipeline expanding internationally. DexCom launched Dexcom Flex in Germany (May 2026), a CGM tailored for basal insulin, oral medication, and GLP-1 users — extending the type-2 strategy that has worked domestically into a major European market. A redesigned Stelo app (more AI-driven insights, nutrition/macro tracking) rolled out domestically with an international launch planned later in 2026, and Smart Basal remains in a broadening pilot phase.
7. Regulatory tailwind: FDA TEMPO pilot. On July 22, DexCom was named the first participant in the FDA's new TEMPO digital health device pilot, which uses enforcement discretion to let the company offer an AI-powered glucose tool to Medicare patients ahead of full premarket authorization while generating real-world evidence — a potentially useful bridge toward earlier-stage/prediabetes screening use cases and further CMS engagement.
Abbott remains the U.S. CGM installed-base leader (reported near 48.5% share vs. DexCom's ~44.7% as of 2025, per commentary at JPMorgan's healthcare conference), and is pushing a dual-analyte glucose-ketone sensor strategy alongside broader Diabetes Care distribution. Medtronic is also a competitive factor in the category. DexCom's counter-strategy leans on product differentiation (15 Day wear, Smart Basal, Stelo, Flex), reimbursement execution in underpenetrated type-2 populations, and international access wins (e.g., recent gains in France and Canada, new tender wins converting exclusive competitor contracts to dual-source).
DexCom disclosed in late May that it discovered two lots of scrapped/destroyed product had been stolen by a third party and resold into the market; the company notified the FDA and affected users. This appears to be a contained supply-chain/quality issue rather than a broad product recall, but it's worth a sentence on the call if analysts ask about remediation costs or chain-of-custody controls.
DexCom enters this print with strong underlying fundamentals (record global new-patient adds, margin expansion, raised long-term targets, a fresh $1B buyback) and a supportive newsflow backdrop (positive CONNECT RCT data, incremental CMS movement, FDA TEMPO selection, new international product launches). Multiple sell-side firms have raised price targets into the print (e.g., Truist to $87, Deutsche Bank initiating at $86), reflecting building confidence — which also raises the bar for what the market will consider a "good enough" quarter. The most market-moving elements are likely to be (1) any change to full-year guidance, (2) fresh detail on U.S. new-patient/15-Day conversion trends, and (3) any incremental signal on CMS coverage timing for the type-2 non-insulin population, which remains the single largest structural catalyst for the U.S. business.